Rafael Holdings Q1 FY2026 net loss $9.8M; Phase 3 NPC trial continues

Rafael Holdings, Inc.

2026-Q1 EPS reported -$0.19 revenue$240,000

Net loss attributable to Rafael Holdings of $9.8M ($0.19/shr), widened from $9.0M ($0.37/shr) YoY.
R&D expenses $7.5M vs $1.3M YoY, driven by Cyclo Therapeutics consolidation after March 2025 acquisition.
Cash and cash equivalents $45.5M as of October 31, 2025.
CEO Howard Jonas highlighted Phase 3 TransportNPC study for Trappsol Cyclo; DMC recommended continue after 48-week data.
General & administrative expenses $2.8M vs $2.5M YoY, also due to Cyclo consolidation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.